Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | PARG | Q86W56 | 2/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17610841 | 0.88 | RORC (0.41) | TRPV4RORC | |
| SCHEMBL286670 | 0.85 | DAO (0.46) | TRPV4DAOKCNJ1KCNH2 | |
| SCHEMBL17610661 | 0.83 | MRGPRX4 (0.43) | CA2CA9KCNH2CA1MRGPRX4 | |
| SCHEMBL17610774 | 0.83 | TRPV4 (0.40) | TRPV4 | |
| SCHEMBL20300564 | 0.82 | MRGPRX4 (0.42) | TRPV4KCNJ1CA2CA9KCNH2 | |
| SCHEMBL17610723 | 0.81 | ALDH1A1 (0.47) | CA2CA9CA1 | |
| SCHEMBL17610838 | 0.81 | AR (0.43) | KCNJ1KCNH2 | |
| SCHEMBL17610646 | 0.80 | CA2 (0.37) | CA2CA9CA1FFAR1MRGPRX4 | |
| SCHEMBL16892292 | 0.79 | TRPV4 (0.52) | TRPV4DAOCYP11B1CYP11B2 | |
| SCHEMBL31605567 | 0.79 | TRPV4 (0.52) | TRPV4DAOCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3475275-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017222951-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-7803954-B2 | Competitive and selective inhibitors of trypsin-like serine proteases involved in hemostasis; anticoagulants; Ph(3-Cl)(5-OCHF2) (R)CH(OH)C(O)-Aze-Pab(OMe); oral administration; gelling matrix modified-release system | ASTRAZENECA AB (SE) | 2010-09-28 | — | — | US | disclosed |
| EP-2186800-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | Astra Zeneca AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | INGHARDT TORD | 2010-04-08 | — | — | US | disclosed |
| EP-1347955-B1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7645751-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20080090800-A1 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2008-04-17 | — | — | US | disclosed |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-09-20 | — | — | US | disclosed |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-08-30 | — | — | US | disclosed |
| US-7129233-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20060052314-A1 | Pharmaceutical combination | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090800-A1 | Mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | TRPV4 4020/4885DAO 279/4885RORC 2812/4885 |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | TRPV4 3575/4885DAO 169/4885RORC 3860/4885 |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | TFPI, F2R, F2 | TRPV4 4080/4885DAO 280/4885RORC 3130/4885 |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | HDAC6, HDAC1, HDAC5 | TRPV4 4711/4885DAO 833/4885RORC 430/4885 |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | TRPV4 4080/4885DAO 280/4885RORC 3130/4885 |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | HDAC6, HDAC1, HDAC5 | TRPV4 4711/4885DAO 833/4885RORC 430/4885 |
| US-20060052314-A1 | Pharmaceutical combination | F2, TNNT2, WFS1 | TRPV4 723/4885DAO 560/4885RORC 1377/4885 |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | TRPV4 4080/4885DAO 280/4885RORC 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.